Royalty Pharma (RPRX) Offers Attractive Risk-Reward Profiles at Reasonable Multiples Soumya Eswaran Mon, October 12, 2026 at 11:18 AM EDT 3 min read RPRX +0.39% SPGI +1.36% ^GSPC -0.06% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Patient Capital Management, based in Baltimore, released its third-quarter 2026 investor letter for the "Patient Opportunity Equity Strategy". The letter can be downloaded here. The Opportunity Equity Strategy outperformed the S&P 500 in the latest quarter, gaining 4.32% compared to 2.30%, and is up 14.93% year-to-date versus the index's 12.75%. The market shows resilience, despite rate increases presenting risks and opportunities. The current market is seen as part of a long bull run, especially since March 2009, with the S&P compounding at 16.9% per year. The AI revolution adds complexity, and investor skepticism persists amidst rising valuations, yet strong corporate earnings suggest potential. The focus remains on understanding price expectations and evaluating risks, particularly around AI durability and supply-demand for computing capacity. The portfolio is concentrated in top 10 holdings, suggesting a disciplined approach towards valuation and risk management amidst market volatility. Also, check the strategy's top five holdings to see its best picks in 2026.
In its Q3 2026 investor letter, Patient Opportunity Equity Strategy highlighted Royalty Pharma plc (NASDAQ:RPRX). Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical investment company that specializes in acquiring royalty interests and funding innovation in the biopharmaceutical industry. On October 09, 2026, Royalty Pharma plc (NASDAQ:RPRX) closed at $56.93 per share, reflecting a market capitalization of $32.74 billion. Royalty Pharma plc (NASDAQ:RPRX) posted a one-month return of -3.10%, and its shares gained 61.46% over the past 52 weeks.
Patient Opportunity Equity Strategy stated the following regarding Royalty Pharma plc (NASDAQ:RPRX) in its Q3 2026 investor letter:
"Royalty Pharma plc (NASDAQ:RPRX) ($56.21) and United Healthcare (UNH $370.95) are significant contributors for the year, but we continue to like the risk-reward in each. Royalty Pharma is a master capital allocator providing critical funding for the biopharma industry. They dominate the market for large deals. With a return on capital in the high teens and low-to mid-teens earnings growth, we think its 16.7x 2027 owners' earnings3 multiple remains attractive. For the next few years, earnings should grow in the mid-teens in most environments. Both companies add ballast to the portfolio."
Royalty Pharma plc (NASDAQ:RPRX) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 47 hedge fund portfolios held Royalty Pharma plc (NASDAQ:RPRX) at the end of the second quarter, which was 42 in the previous quarter. While we acknowledge the potential of Royalty Pharma plc (NASDAQ:RPRX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
In another article, we discussed Royalty Pharma plc (NASDAQ:RPRX) and noted that Novartis's failed Phase 3 pelacarsen trial shifts the primary value of its $500M Ionis transaction to Spinraza recovery. In addition, please check out our hedge fund investor letters Q3 2026 page for more investor letters from hedge funds and other leading investors.
This article is originally published at Insider Monkey.
